Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants

NCT07050511 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS CoV-2

Interventions

DRUG: GB-0669
DRUG: Placebo

Sponsor

Generate Biomedicines